Adjunctive sertraline for HIV-associated cryptococcal meningitis: a randomised, placebo-controlled, double-blind phase 3 trial
| dc.contributor.author | Rhein, Joshua | |
| dc.contributor.author | Tugume, Lillian | |
| dc.contributor.author | Nuwagira, Edwin | |
| dc.contributor.author | Mpoza, Edward | |
| dc.contributor.author | Kiggundu, Reuben | |
| dc.contributor.author | Ssebambulidde, Kenneth | |
| dc.contributor.author | Boulware, David R. | |
| dc.date.accessioned | 2025-04-03T17:41:44Z | |
| dc.date.available | 2025-04-03T17:41:44Z | |
| dc.date.issued | 2019-08-30 | |
| dc.description.abstract | Identifying new antifungals for cryptococcal meningitis is a priority given the inadequacy of current therapy. Sertraline has previously shown in vitro and in vivo activity against cryptococcus. We aimed to assess the efficacy and cost-effectiveness of adjunctive sertraline in adults with HIV-associated cryptococcal meningitis compared with placebo. | |
| dc.identifier.citation | Rhein, J., Hullsiek, K. H., Tugume, L., Nuwagira, E., Mpoza, E., Evans, E. E., ... & Nielsen, K. (2019). Adjunctive sertraline for HIV-associated cryptococcal meningitis: a randomised, placebo-controlled, double-blind phase 3 trial. The Lancet infectious diseases, 19(8), 843-851. | |
| dc.identifier.other | doi: 10.1016/S1473-3099(19)30127-6 | |
| dc.identifier.uri | https://nru.uncst.go.ug/handle/123456789/10352 | |
| dc.language.iso | en | |
| dc.publisher | The Lancet infectious diseases | |
| dc.title | Adjunctive sertraline for HIV-associated cryptococcal meningitis: a randomised, placebo-controlled, double-blind phase 3 trial | |
| dc.type | Article |